The use of intravenous and subcutaneous Tanezumab injections is associated with an effective reduction in the intensity of chronic low back pain (CLBP), according to a meta-analysis of randomized controlled trials. Researchers sought to determine the effectiveness of various Tanezumab dosing regimens among people with CLBP.

Electronic databases like the Cochrane Library, Embase, PubMed, and others were explored for relevant literature searches.  Randomized controlled trials exploring Tanezumab's efficacy and safety in CLBP-affected people were included. Notably, 2 researchers independently extracted the data. Using the Cochrane risk-of-bias tool, the study's quality was determined. The Roland-Morris Disability Questionnaire and low back pain intensity were measured. To substantiate Tanezumab's safety for CLBP, the occurrence of adverse events and major adverse events was analyzed.

Overall, 3414 subjects from 3 high-quality randomized controlled trials were incorporated in the analysis. Tanezumab significantly reduced both the Roland-Morris Disability Questionnaire (mean difference, -0.64) and low back pain intensity (mean difference, -0.62) when compared to the placebo. There was no discernible difference in adverse events (risk ratio, 1.06) and major adverse events (risk ratio, 1.10) between the Tanezumab and placebo groups.

Thus, Tanezumab injections given intravenously and subcutaneously have promising clinical applications and controllable safety issues. Additionally, through the subgroup analysis and comparison, intravenous and subcutaneous tanezumab injections were proved to attain outstanding and long-term curative effects in CLBP-affected people.